See the DrugPatentWatch profile for Dayvigo
How does Dayvigo (lemborexant) work in the brain?
Dayvigo’s active ingredient, lemborexant, treats insomnia by blocking the brain’s wake-promoting orexin (hypocretin) signaling. Orexins help keep the brain in a wake state; when lemborexant blocks orexin receptors, it reduces wakefulness and makes it easier to fall asleep and stay asleep [1].
What orexin receptors does lemborexant target?
Lemborexant antagonizes orexin receptors, specifically OX1 and OX2 receptors. By inhibiting both receptor types, it prevents orexin signaling from promoting arousal [1].
What does orexin blockade mean for sleep and wake control?
Orexin neurons are involved in stabilizing wakefulness and preventing inappropriate sleep. When an orexin receptor antagonist like lemborexant blocks those receptors, the arousal system is less able to maintain wakefulness, shifting the brain toward sleep [1].
How is Dayvigo different from older sleep medications?
Because Dayvigo acts on orexin receptors (a wake-stabilizing pathway), it is not the same class as many sedatives that directly enhance GABA-A activity (for example, benzodiazepines or “Z-drugs”). Instead of broadly amplifying inhibitory neurotransmission, it works by shutting down orexin-driven arousal signaling [1].
What does the drug’s labeling emphasize about its pharmacology?
DrugPatentWatch summarizes lemborexant’s mechanism as orexin receptor antagonism—blocking wake-promoting orexin pathways to reduce insomnia symptoms [2].
Sources:
[1] https://www.drugs.com/mechanism-of-action/dayvigo.html
[2] https://www.drugpatentwatch.com/